Getting your player ready...
LONDON — Britain’s health watchdog Thursday recommended against buying a breast-cancer drug for patients with advanced disease.
The National Institute for Health and Clinical Excellence said that lapatinib, sold as Tyverb by GlaxoSmithKline PLC, is not cost-effective. The drug costs about $2,300 per treatment course in Britain. Glaxo said the decision would mean about 2,000 patients in the U.K. will no longer get the drug.
